Hallmarks of Resistance to Immune-Checkpoint Inhibitors

Immune-checkpoint inhibitors (ICI), although revolutionary in improving long-term survival outcomes, are mostly effective in patients with immune-responsive tumors. Most patients with cancer either do not respond to ICIs at all or experience disease progression after an initial period of response. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Karasarides, Maria, Cogdill, Alexandria P., Robbins, Paul B., Bowden, Michaela, Burton, Elizabeth M., Butterfield, Lisa H., Cesano, Alessandra, Hammer, Christian, Haymaker, Cara L., Horak, Christine E., McGee, Heather M., Monette, Anne, Rudqvist, Nils-Petter, Spencer, Christine N., Sweis, Randy F., Vincent, Benjamin G., Wennerberg, Erik, Yuan, Jianda, Zappasodi, Roberta, Lucey, Vanessa M. Hubbard, Wells, Daniel K., LaVallee, Theresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381103/
https://www.ncbi.nlm.nih.gov/pubmed/35362046
http://dx.doi.org/10.1158/2326-6066.CIR-20-0586

Ejemplares similares

Ejemplares similares